#BEGIN_DRUGCARD DB02007

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
17665

# Chemical_Formula:
C6H13O9P

# Chemical_IUPAC_Name:
{[(2S,3R,4R,5S,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy}phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Mol_Id: 1

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Alpha-D-Glucose-6-Phosphate

# HET_ID:
G6P

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C6H13O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5-,6-/m0/s1

# InChI_Key:
InChIKey=NBSCHQHZLSJFNQ-QYESYBIKSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00668

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2007

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
260.1358

# Molecular_Weight_Mono:
260.029718526

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1CZA

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.1

# Predicted_LogS:
-0.92

# Predicted_Water_Solubility:
3.14e+01 g/l

# Primary_Accession_No:
DB02007

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936284

# PubChem_Substance_ID:
46505235

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01537

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O[C@H]1O[C@@H](COP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:42 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Mitochondrion
mitochondrial outer membrane. Note=Its hydrophobic N-terminal sequence may be involve

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
HK1

# Drug_Target_1_GenBank_ID_Gene:
M75126

# Drug_Target_1_GenBank_ID_Protein:
184021

# Drug_Target_1_GeneCard_ID:
HK1

# Drug_Target_1_Gene_Name:
HK1

# Drug_Target_1_Gene_Sequence:
>2754 bp
ATGATCGCCGCGCAGCTCCTGGCCTATTACTTCACGGAGCTGAAGGATGACCAGGTCAAA
AAGATTGACAAGTATCTGTATGCCATGCGGCTCTCCGATGAAACTCTCATAGATATCATG
ACTCGCTTCAGGAAGGAGATGAAGAATGGCCTCTCCCGGGATTTTAATCCAACAGCCACA
GTCAAGATGTTGCCAACATTCGTAAGGTCCATTCCTGATGGCTCTGAAAAGGGAGATTTC
ATTGCCCTGGATCTTGGTGGGTCTTCCTTTCGAATTCTGCGGGTGCAAGTGAATCATGAG
AAAAACCAGAATGTTCACATGGAGTCCGAGGTTTATGACACCCCAGAGAACATCGTGCAC
GGCAGTGGAAGCCAGCTTTTTGATCATGTTGCTGAGTGCCTGGGAGATTTCATGGAGAAA
AGGAAGATCAAGGACAAGAAGTTACCTGTGGGATTCACGTTTTCTTTTCCTTGCCAACAA
TCCAAAATAGATGAGGCCATCCTGATCACCTGGACAAAGCGATTTAAAGCGAGCGGAGTG
GAAGGAGCAGATGTGGTCAAACTGCTTAACAAAGCCATCAAAAAGCGAGGGGACTATGAT
GCCAACATCGTAGCTGTGGTGAATGACACAGTGGGCACCATGATGACCTGTGGCTATGAC
GACCAGCACTGTGAAGTCGGCCTGATCATCGGCACTGGCACCAATGCTTGCTACATGGAG
GAACTGAGGCACATTGATCTGGTGGAAGGAGACGAGGGGAGGATGTGTATCAATACAGAA
TGGGGAGCCTTTGGAGACGATGGATCATTAGAAGACATCCGGACAGAGTTTGACAGGGAG
ATAGACCGGGGATCCCTCAACCCTGGAAAACAGCTGTTTGAGAAGATGGTCAGTGGCATG
TACTTGGGAGAGCTGGTTCGACTGATCCTAGTCAAGATGGCCAAGGAGGGCCTCTTATTT
GAAGGGCGGATCACCCCGGAGCTGCTCACCCGAGGGAAGTTTAACACCAGTGATGTGTCA
GCCATCGAAAAGAATAAGGAAGGCCTCCACAATGCCAAAGAAATCCTGACCCGCCTGGGA
GTGGAGCCGTCCGATGATGACTGTGTCTCAGTCCAGCACGTTTGCACCATTGTCTCATTT
CGCTCAGCCAACTTGGTGGCTGCCACACTGGGCGCCATCTTGAACCGCCTGCGTGATAAC
AAGGGCACACCCAGGCTGCGGACCACGGTTGGTGTCGACGGATCTCTTTACAAGACGCAC
CCACAGTATTCCCGGCGTTTCCACAAGACTCTAAGGCGCTTGGTGCCAGACTCCGATGTG
CGCTTCCTCCTCTCGGAGAGTGGCAGCGGCAAGGGGGCTGCCATGGTGACGGCGGTGGCC
TACCGCTTGGCCGAGCAGCACCGGCAGATAGAGGAGACCCTGGCTCATTTCCACCTCACC
AAAGACATGCTGCTGGAGGTGAAGAAGAGGATGCGGGCCGAGATGGAGCTGGGGCTGAGG
AAGCAGACGCACAACAATGCCGTGGTTAAGATGCTGCCCTCCTTCGTCCGGAGAACTCCC
GACGGGACCGAGAATGGTGACTTCTTGGCCCTGGATCTTGGAGGAACCAATTTCCGTGTG
CTGCTGGTGAAAATCCGTAGTGGGAAAAAGAGAACGGTGGAAATGCACAACAAGATCTAC
GCCATTCCTATTGAAATCATGCAGGGCACTGGGGAAGAGCTGTTTGATCACATTGTCTCC
TGCATCTCTGACTTCTTGGACTACATGGGGATCAAAGGCCCCAGGATGCCTCTGGGCTTC
ACGTTCTCATTTCCCTGCCAGCAGACGAGTCTGGACGCGGGAATCTTGATCACGTGGACA
AAGGGTTTTAAGGCAACAGACTGCGTGGGCCACGATGTAGTCACCTTACTAAGGGATGCG
ATAAAAAGGAGAGAGGAATTTGACCTGGACGTGGTGGCTGTGGTCAACGACACAGTGGGC
ACCATGATGACCTGTGCTTATGAGGAGCCCACCTGTGAGGTTGGACTCATTGTTGGGACC
GGCAGCAATGCCTGCTACATGGAGGAGATGAAGAACGTGGAGATGGTGGAGGGGGACCAG
GGGCAGATGTGCATCAACATGGAGTGGGGGGCCTTTGGGGACAACGGGTGTCTGGATGAT
ATCAGGACACACTACGACAGACTGGTGAACGAATATTCCCTAAATGCTGGGAAACAAAGG
TATGAGAAGATGATCAGTGGTATGTACCTGGGTGAAATCGTCCGCAACATCTTAATCGAC
TTCACCAAGAAGGGATTCCTCTTCCGAGGGCAGATCTCTGAGACGATGAAGACCCGGGGC
ATCTTTGAGACCAAGTTTCTCTCTCAGATCGAGAGTGACCGATTAGCACTGCTCCAGGTC
CGGGCTATCCTCCAGCAGCTAGGTCTGAATAGCACCTGCGATGACAGTATCCTCGTCAAG
ACAGTGTGCGGGGTGGTGTCCAGGAGGGCCGCACAGCTGTGTGGCGCAGGCATGGCTGCG
GTTGTGGATAAGATCCGCGAGAACAGAGGACTGGACCGTCTGAATGTGACTGTGGGAGTG
GACGGGACACTCTACAAGCTTCATCCACACTTCTCCAGAATCATGCACCAGACGGTGAAG
GAACTGTCACCAAAATGTAACGTGTCCTTCCTCCTGTCTGAGGATGGCAGCGGCAAGGGG
GCCGCCCTCATCACGGCCGTGGGCGTGCGGTTACGCACAGAGGCAAGCAGCTAA

# Drug_Target_1_General_Function:
Involved in hexokinase activity

# Drug_Target_1_General_References:
10574795	Rosano C, Sabini E, Rizzi M, Deriu D, Murshudov G, Bianchi M, Serafini G, Magnani M, Bolognesi M: Binding of non-catalytic ATP to human hexokinase I highlights the structural components for enzyme-membrane association control. Structure. 1999 Nov 15;7(11):1427-37.
10686099	Aleshin AE, Kirby C, Liu X, Bourenkov GP, Bartunik HD, Fromm HJ, Honzatko RB: Crystal structures of mutant monomeric hexokinase I reveal multiple ADP binding sites and conformational changes relevant to allosteric regulation. J Mol Biol. 2000 Mar 3;296(4):1001-15.
10978502	Andreoni F, Ruzzo A, Magnani M: Structure of the 5' region of the human hexokinase type I (HKI) gene and identification of an additional testis-specific HKI mRNA. Biochim Biophys Acta. 2000 Sep 7;1493(1-2):19-26.
1637300	Magnani M, Bianchi M, Casabianca A, Stocchi V, Daniele A, Altruda F, Ferrone M, Silengo L: A recombinant human 'mini'-hexokinase is catalytically active and regulated by hexose 6-phosphates. Biochem J. 1992 Jul 1;285 ( Pt 1):193-9.
1985912	Magnani M, Serafini G, Bianchi M, Casabianca A, Stocchi V: Human hexokinase type I microheterogeneity is due to different amino-terminal sequences. J Biol Chem. 1991 Jan 5;266(1):502-5.
3207429	Nishi S, Seino S, Bell GI: Human hexokinase: sequences of amino- and carboxyl-terminal halves are homologous. Biochem Biophys Res Commun. 1988 Dec 30;157(3):937-43.
7655856	Bianchi M, Magnani M: Hexokinase mutations that produce nonspherocytic hemolytic anemia. Blood Cells Mol Dis. 1995;21(1):2-8.
8706938	Aleshin AE, Zeng C, Fromm HJ, Honzatko RB: Crystallization and preliminary X-ray analysis of human brain hexokinase. FEBS Lett. 1996 Aug 5;391(1-2):9-10.
9028305	Murakami K, Piomelli S: Identification of the cDNA for human red blood cell-specific hexokinase isozyme. Blood. 1997 Feb 1;89(3):762-6.
9493266	Aleshin AE, Zeng C, Bourenkov GP, Bartunik HD, Fromm HJ, Honzatko RB: The mechanism of regulation of hexokinase: new insights from the crystal structure of recombinant human brain hexokinase complexed with glucose and glucose-6-phosphate. Structure. 1998 Jan 15;6(1):39-50.
9531504	Ruzzo A, Andreoni F, Magnani M: Structure of the human hexokinase type I gene and nucleotide sequence of the 5' flanking region. Biochem J. 1998 Apr 15;331 ( Pt 2):607-13.
9735292	Aleshin AE, Zeng C, Bartunik HD, Fromm HJ, Honzatko RB: Regulation of hexokinase I: crystal structure of recombinant human brain hexokinase complexed with glucose and phosphate. J Mol Biol. 1998 Sep 18;282(2):345-57.

# Drug_Target_1_HGNC_ID:
HGNC:4922

# Drug_Target_1_HPRD_ID:
00809

# Drug_Target_1_ID:
1881

# Drug_Target_1_Locus:
10q22

# Drug_Target_1_Molecular_Weight:
102487

# Drug_Target_1_Name:
Hexokinase-1

# Drug_Target_1_Number_of_Residues:
917

# Drug_Target_1_PDB_ID:
1HKB

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00349	Hexokinase_1
PF03727	Hexokinase_2

# Drug_Target_1_Protein_Sequence:
>Hexokinase-1
MIAAQLLAYYFTELKDDQVKKIDKYLYAMRLSDETLIDIMTRFRKEMKNGLSRDFNPTAT
VKMLPTFVRSIPDGSEKGDFIALDLGGSSFRILRVQVNHEKNQNVHMESEVYDTPENIVH
GSGSQLFDHVAECLGDFMEKRKIKDKKLPVGFTFSFPCQQSKIDEAILITWTKRFKASGV
EGADVVKLLNKAIKKRGDYDANIVAVVNDTVGTMMTCGYDDQHCEVGLIIGTGTNACYME
ELRHIDLVEGDEGRMCINTEWGAFGDDGSLEDIRTEFDREIDRGSLNPGKQLFEKMVSGM
YLGELVRLILVKMAKEGLLFEGRITPELLTRGKFNTSDVSAIEKNKEGLHNAKEILTRLG
VEPSDDDCVSVQHVCTIVSFRSANLVAATLGAILNRLRDNKGTPRLRTTVGVDGSLYKTH
PQYSRRFHKTLRRLVPDSDVRFLLSESGSGKGAAMVTAVAYRLAEQHRQIEETLAHFHLT
KDMLLEVKKRMRAEMELGLRKQTHNNAVVKMLPSFVRRTPDGTENGDFLALDLGGTNFRV
LLVKIRSGKKRTVEMHNKIYAIPIEIMQGTGEELFDHIVSCISDFLDYMGIKGPRMPLGF
TFSFPCQQTSLDAGILITWTKGFKATDCVGHDVVTLLRDAIKRREEFDLDVVAVVNDTVG
TMMTCAYEEPTCEVGLIVGTGSNACYMEEMKNVEMVEGDQGQMCINMEWGAFGDNGCLDD
IRTHYDRLVDEYSLNAGKQRYEKMISGMYLGEIVRNILIDFTKKGFLFRGQISETLKTRG
IFETKFLSQIESDRLALLQVRAILQQLGLNSTCDDSILVKTVCGVVSRRAAQLCGAGMAA
VVDKIRENRGLDRLNVTVGVDGTLYKLHPHFSRIMHQTVKELSPKCNVSFLLSEDGSGKG
AALITAVGVRLRTEASS

# Drug_Target_1_Reaction:
ATP + D-hexose = ADP + D-hexose 6-phosphate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
ATP + D-hexose = ADP + D-hexose 6-phosphate

# Drug_Target_1_SwissProt_ID:
P19367

# Drug_Target_1_SwissProt_Name:
HXK1_HUMAN

# Drug_Target_1_Synonyms:
Brain form hexokinase
EC 2.7.1.1
HK I
Hexokinase type I

# Drug_Target_1_Theoretical_pI:
6.78

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M60873

# Drug_Target_2_GenBank_ID_Protein:
150994

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
algC

# Drug_Target_2_Gene_Sequence:
>1392 bp
ATGAGCACTGTAAAAGCACCGACGCTGCCCGCCAGCATCTTCCGCGCCTACGACATCCGT
CGCGTGGTAGGCGATACCCTCACCGCCGAGACCGCCTACTGGATCGGTCGCGCCATCGGC
TCGGAAAGCCTCGCCCGCGGCGAACCGTGCGTCGCTGTCGGCCGCGATGGCCGCCTGTCC
GGTCCCGAGCTGGTCAAGCAGCTGATCCAGGGCCTGGTGGACTGCGGTTGCCAGGTCAGC
GACGTGGGCATGGTGCCTACCCCGGTGCTGTACTACGCGGCCAACGTGCTCGAGGGCAAG
TCCGGGGTGATGCTGACCGGCAGCCACAATCCGCCGGACTACAACGGCTTCAAGATCGTG
GTCGCCGGCGAGACCCTGGCCAACGAGCAGATCCAGGCCCTGCGCGAGCGCATCGAGAAA
AACGACCTGGCATCCGGCGTCGGCAGCGTAGAGCAGGTCGACATCCTGCCGCGCTACTTC
AAGCAGATCCGCGACGACATCGCCATGGCCAAGCCGATGAAGGTGGTGGTCGACTGCGGC
AACGGCGTGGCCGGGGTGATCGCCCCGCAGTTGATCGAGGCCCTGGGCTGCAGCGTGATC
CCGCTGTACTGCGAGGTCGACGGCAACTTCCCGAACCACCATCCGGACCCGGGCAAGCCG
GAGAACCTGAAGGACCTGATCGCCAAGGTCAAGGCCGAGAACGCCGACCTGGGCCTGGCC
TTCGACGGCGACGGCGATCGCGTCGGCGTGGTCACCAATACCGGTACCATCATCTATCCG
GACCGTCTGCTGATGCTGTTCGCCAAGGACGTGGTCTCGCGCAACCCGGGGGCCGACATC
ATCTTCGACGTCAAGTGCACCCGCCGTCTGATCGCCCTGATCAGCGGCTACGGCGGCCGT
CCGGTGATGTGGAAGACCGGCCACTCGCTGATCAAGAAGAAGATGAAGGAAACCGGCGCC
CTGCTGGCTGGCGAGATGAGCGGCCACGTGTTCTTCAAGGAGCGCTGGTTCGGCTTCGAC
GATGGCATCTACAGCGCCGCCCGCCTGCTGGAAATCCTCAGCCAGGATCAGCGTGACAGC
GAGCACGTGTTCTCGGCCTTCCCGAGCGACATTTCCACCCCGGAAATCAACATCACCGTC
ACCGAGGACAGCAAGTTCGCCATCATCGAGGCGCTGCAACGCGACGCCCAATGGGGCGAA
GGCAACATCACCACCCTCGACGGCGTGCGGGTCGACTACCCCAAAGGCTGGGGCCTGGTA
CGCGCCTCCAACACCACTCCCGTGCTGGTCCTGCGCTTCGAAGCGGACCCCGAGGAAGAG
CTGGAGCGCATCAAGACCGTCTTCCGTAACCAACTGAAGGCAGTGGATTCCTCGCTGCCC
GTGCCCTTCTGA

# Drug_Target_2_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_2_General_References:
10481091	Olvera C, Goldberg JB, Sanchez R, Soberon-Chavez G: The Pseudomonas aeruginosa algC gene product participates in rhamnolipid biosynthesis. FEMS Microbiol Lett. 1999 Oct 1;179(1):85-90.
10984043	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature. 2000 Aug 31;406(6799):959-64.
11716469	Naught LE, Tipton PA: Kinetic mechanism and pH dependence of the kinetic parameters of Pseudomonas aeruginosa phosphomannomutase/phosphoglucomutase. Arch Biochem Biophys. 2001 Dec 1;396(1):111-8.
11839312	Regni C, Tipton PA, Beamer LJ: Crystal structure of PMM/PGM: an enzyme in the biosynthetic pathway of P. aeruginosa virulence factors. Structure. 2002 Feb;10(2):269-79.
1903398	Zielinski NA, Chakrabarty AM, Berry A: Characterization and regulation of the Pseudomonas aeruginosa algC gene encoding phosphomannomutase. J Biol Chem. 1991 May 25;266(15):9754-63.
7515870	Coyne MJ Jr, Russell KS, Coyle CL, Goldberg JB: The Pseudomonas aeruginosa algC gene encodes phosphoglucomutase, required for the synthesis of a complete lipopolysaccharide core. J Bacteriol. 1994 Jun;176(12):3500-7.
8050998	Ye RW, Zielinski NA, Chakrabarty AM: Purification and characterization of phosphomannomutase/phosphoglucomutase from Pseudomonas aeruginosa involved in biosynthesis of both alginate and lipopolysaccharide. J Bacteriol. 1994 Aug;176(16):4851-7.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2503

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
50296

# Drug_Target_2_Name:
Phosphomannomutase/phosphoglucomutase

# Drug_Target_2_Number_of_Residues:
463

# Drug_Target_2_PDB_ID:
1K2Y

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00408	PGM_PMM_IV
PF02878	PGM_PMM_I
PF02879	PGM_PMM_II
PF02880	PGM_PMM_III

# Drug_Target_2_Protein_Sequence:
>Phosphomannomutase/phosphoglucomutase
MSTAKAPTLPASIFRAYDIRGVVGDTLTAETAYWIGRAIGSESLARGEPCVAVGRDGRLS
GPELVKQLIQGLVDCGCQVSDVGMVPTPVLYYAANVLEGKSGVMLTGSHNPPDYNGFKIV
VAGETLANEQIQALRERIEKNDLASGVGSVEQVDILPRYFKQIRDDIAMAKPMKVVVDCG
NGVAGVIAPQLIEALGCSVIPLYCEVDGNFPNHHPDPGKPENLKDLIAKVKAENADLGLA
FDGDGDRVGVVTNTGTIIYPDRLLMLFAKDVVSRNPGADIIFDVKCTRRLIALISGYGGR
PVMWKTGHSLIKKKMKETGALLAGEMSGHVFFKERWFGFDDGIYSAARLLEILSQDQRDS
EHVFSAFPSDISTPEINITVTEDSKFAIIEALQRDAQWGEGNITTLDGVRVDYPKGWGLV
RASNTTPVLVLRFEADTEEELERIKTVFRNQLKAVDSSLPVPF

# Drug_Target_2_Reaction:
alpha-D-glucose 1-phosphate = D-glucose 6-phosphate

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
The phosphomannomutase activity produces a precursor for alginate polymerization. The alginate layer causes a mucoid phenotype and provides a protective barrier against host immune defenses and antibiotics. Also involved in core-LPS biosynthesis due to its phosphoglucomutase activity. Essential for rhamnolipid production, an exoproduct correlated with pathogenicity, and for biofilm production

# Drug_Target_2_SwissProt_ID:
P26276

# Drug_Target_2_SwissProt_Name:
ALGC_PSEAE

# Drug_Target_2_Synonyms:
EC 5.4.2.2
EC 5.4.2.8
PMM / PGM

# Drug_Target_2_Theoretical_pI:
4.95

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasmic

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
D50543

# Drug_Target_3_GenBank_ID_Protein:
1486241

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
glvA

# Drug_Target_3_Gene_Sequence:
>1350 bp
ATGAAGAAAAAATCATTCTCAATCGTAATAGCGGGCGGAGGGAGCACTTTCACTCCAGGG
ATCGTACTCATGCTCTTGGACCATTTGGAGGAGTTTCCGATCAGAAAGCTGAAGCTGTAT
GATAATGATAAGGAGAGACAGGATCGAATTGCAGGCGCCTGTGACGTTTTTATCAGAGAA
AAAGCGCCGGATATTGAATTTGCAGCGACGACTGACCCGGAAGAAGCTTTTACAGATGTC
GATTTTGTTATGGCGCACATCAGAGTAGGGAAATACGCGATGCGCGCGCTTGATGAGCAA
ATTCCGTTAAAGTACGGAGTTGTCGGCCAGGAGACGTGCGGGCCGGGCGGGATCGCATAC
GGTATGCGTTCGATCGGCGGTGTGCTTGAAATATTAGATTACATGGAAAAATACTCGCCT
GATGCGTGGATGCTCAATTATTCCAATCCGGCGGCAATTGTGGCTGAAGCTACGAGACGC
CTTAGACCGAATTCTAAAATTCTCAATATCTGTGATATGCCGGTTGGGATCGAAGACCGG
ATGGCGCAAATTCTTGGCTTATCCTCAAGAAAAGAAATGAAGGTCCGCTATTACGGATTG
AATCATTTCGGCTGGTGGACATCGATTCAGGATCAAGAGGGCAACGATTTAATGCCGAAG
CTGAAGGAACATGTATCCCAATACGGTTATATTCCGAAAACAGAGGCTGAAGCTGTGGAG
GCAAGCTGGAATGACACGTTCGCCAAAGCGCGTGACGTGCAGGCTGCAGATCCTGACACA
CTGCCGAATACGTATTTGCAATATTATTTGTTCCCAGATGATATGGTGAAAAAATCAAAT
CCGAATCATACGCGGGCGAATGAAGTCATGGAAGGGCGCGAAGCTTTTATTTTCAGCCAA
TGTGACATGATCACACGTGAACAGTCCTCGGAAAACAGCGAAATTAAAATCGATGACCAC
GCATCGTATATCGTTGATCTTGCCCGGGCGATTGCCTACAACACAGGTGAAAGAATGCTG
TTGATTGTTGAAAATAACGGTGCAATTGCGAACTTTGACCCGACTGCGATGGTTGAGGTG
CCATGCATCGTCGGCTCAAATGGACCTGAACCGATTACCGTTGGCACCATTCCGCAATTC
CAGAAAGGGCTCATGGAGCAGCAGGTATCCGTTGAGAAGCTGACTGTTGAAGCGTGGGCA
GAGAAATCGTTCCAAAAGCTGTGGCAGGCGCTGATCCTGTCAAAAACAGTGCCGAACGCG
CGTGTGGCAAGACTCATTCTTGAGGATTTAGTGGAGGCCAACAAAGACTTCTGGCCTGAG
CTTGATCAAAGCCCAACCCGCATATCATAA

# Drug_Target_3_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_3_General_References:
10329789	Varrot A, Yamamoto H, Sekiguchi J, Thompson J, Davies GJ: Crystallization and preliminary X-ray analysis of the 6-phospho-alpha-glucosidase from Bacillus subtilis. Acta Crystallogr D Biol Crystallogr. 1999 Jun;55(Pt 6):1212-4.
11489864	Yamamoto H, Serizawa M, Thompson J, Sekiguchi J: Regulation of the glv operon in Bacillus subtilis: YfiA (GlvR) is a positive regulator of the operon that is repressed through CcpA and cre. J Bacteriol. 2001 Sep;183(17):5110-21.
8704981	Yamamoto H, Uchiyama S, Fajar AN, Ogasawara N, Sekiguchi J: Determination of a 12 kb nucleotide sequence around the 76 degrees region of the Bacillus subtilis chromosome. Microbiology. 1996 Jun;142 ( Pt 6):1417-21.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.
9765262	Thompson J, Pikis A, Ruvinov SB, Henrissat B, Yamamoto H, Sekiguchi J: The gene glvA of Bacillus subtilis 168 encodes a metal-requiring, NAD(H)-dependent 6-phospho-alpha-glucosidase. Assignment to family 4 of the glycosylhydrolase superfamily. J Biol Chem. 1998 Oct 16;273(42):27347-56.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2393

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
50514

# Drug_Target_3_Name:
Maltose-6'-phosphate glucosidase

# Drug_Target_3_Number_of_Residues:
449

# Drug_Target_3_PDB_ID:
1U8X

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF02056	Glyco_hydro_4

# Drug_Target_3_Protein_Sequence:
>Maltose-6'-phosphate glucosidase
MKKKSFSIVIAGGGSTFTPGIVLMLLDHLEEFPIRKLKLYDNDKERQDRIAGACDVFIRE
KAPDIEFAATTDPEEAFTDVDFVMAHIRVGKYAMRALDEQIPLKYGVVGQETCGPGGIAY
GMRSIGGVLEILDYMEKYSPDAWMLNYSNPAAIVAEATRRLRPNSKILNICDMPVGIEDR
MAQILGLSSRKEMKVRYYGLNHFGWWTSIQDQEGNDLMPKLKEHVSQYGYIPKTEAEAVE
ASWNDTFAKARDVQAADPDTLPNTYLQYYLFPDDMVKKSNPNHTRANEVMEGREAFIFSQ
CDMITREQSSENSEIKIDDHASYIVDLARAIAYNTGERMLLIVENNGAIANFDPTAMVEV
PCIVGSNGPEPITVGTIPQFQKGLMEQQVSVEKLTVEAWAEKSFQKLWQALILSKTVPNA
RVARLILEDLVEANKDFWPELDQSPTRIS

# Drug_Target_3_Reaction:
maltose 6'-phosphate + H2O = D-glucose + D-glucose 6-phosphate

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Hydrolyzes maltose-6'P and trehalose-6'P. Is involved in the catabolism of alpha-glycosides accumulated via a phosphoenolpyruvate-dependent maltose phosphotransferase system (PEP-PTS)

# Drug_Target_3_SwissProt_ID:
P54716

# Drug_Target_3_SwissProt_Name:
GLVA_BACSU

# Drug_Target_3_Synonyms:
6-phospho-alpha-D- glucosidase
6-phosphoryl-O-alpha-D- glucopyranosyl:phosphoglucohydrolase
EC 3.2.1.122

# Drug_Target_3_Theoretical_pI:
4.67

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
PYGM

# Drug_Target_4_GenBank_ID_Gene:
M32598

# Drug_Target_4_GenBank_ID_Protein:
190784

# Drug_Target_4_GeneCard_ID:
PYGM

# Drug_Target_4_Gene_Name:
PYGM

# Drug_Target_4_Gene_Sequence:
>2529 bp
ATGTCCCGGCCCCTGTCAGACCAAGAGAAAAGAAAGCAAATCAGTGTGCGTGGCCTGGCC
GGCGTGGAGAACGTGACTGAGCTGAAAAAGAACTTCAACCGGCACCTGCATTTCACACTC
GTAAAGGACCGCAATGTGGCCACCCCACGAGACTACTACTTTGCTCTGGCCCATACCGTG
CGCGACCACCTCGTGGGGCGGTGGATCCGCACGCAGCAGCACTACTATGAGAAGGACCCC
AAGAGGATCTACTACCTGTCTTTAGAGTTCTATATGGGACGGACGCTACAGAACACCATG
GTGAACCTGGCCTTAGAGAATGCCTGTGACGAGGCCACCTACCAGCTGGGCCTGGACATG
GAGGAGCTGGAGGAAATTGAGGAGGATGCGGGGCTGGGCAACGGGGGCCTGGGCCGGCTG
GCAGCCTGCTTTCTTGACTCCATGGCAACACTGGGCCTGGCTGCCTATGGCTACGGGATT
CGCTATGAGTTTGGGATTTTTAACCAGAAGATCTCCGGGGGCTGGCAGATGGAGGAGGCC
GATGACTGGCTTCGCTACGGCAACCCCTGGGAGAAGGCCCGGCCCGAGTTCACGCTACCT
GTGCACTTCTACGGCCATGTGGAGCACACCAGCCAGGGTGCCAAGTGGGTGGACACACAG
GTGGTACTGGCCATGCCCTACGATACCCCGGTGCCTGGCTATCGCAACAATGTTGTCAAC
ACCATGCGCCTCTGGTCTGCCAAGGCTCCCAATGACTTCAACCTCAAGGACTTCAATGTC
GGTGGCTACATCCAGGCTGTGTTGGACCGAAACCTGGCGGAGAACATCTCTCGTGTCCTG
TACCCCAATGATAATTTCTTCGAAGGGAAGGAGCTGCGGCTGAAGCAGGAGTATTTCGTG
GTGGCTGCCACCCTCCAGGACATCATCCGTCGCTTCAAGTCTTCCAAGTTCGGCTGCCGT
GATCCCGTGCGCACGAACTTCGATGCCTTCCCAGATAAGGTGGCCATCCAGCTCAATGAC
ACCCACCCCTCCCTGGCCATCCCCGAGCTGATGAGGATCCTGGTGGACCTGGAACGGATG
GACTGGGACAAGGCGTGGGATGTGACAGTGAGGACCTGTGCCTACACCAACCACACGGTG
CTGCCCGAGGCCCTGGAGCGCTGGCCGGTGCACCTCTTGGAGACGCTGCTGCCGCGGCAC
CTCCAGATCATCTACGAGATCAACCAGCGCTTCCTCAACCGGGTGGCGGCCGCATTCCCA
GGGGACGTAGACCGGCTGCGGCGCATGTCGCTGGTGGAGGAGGGCGCAGTGAAGCGCATC
AACATGGCACACCTGTGCATCGCGGGGTCGCACGCCGTCAACGGTGTGGCCCGCATCCAC
TCGGAGATCCTCAAGAAGACCATCTTCAAAGACTTCTATGAGCTGGAGCCTCATAAGTTC
CAGAATAAGACCAACGGCATCACCCCTCGGCGCTGGCTGGTTCTGTGTAACCCCGGGCTG
GCAGAGGTCATTGCTGAGCGCATCGGGGAGGACTTCATCTCTGACCTGGACCAGCTGCGC
AAACTGCTCTCCTTTGTGGATGATGAAGCTTTCATTCGGGATGTGGCCAAAGTGAAGCAG
GAAAACAAGTTGAAGTTTGCTGCCTACCTAGAGAGGGAATACAAAGTCCACATCAACCCC
AACTCACTCTTCGACATCCAGGTGAAGCGGATTCACGAATATAAACGACAGCTCCTCAAC
TGCCTCCATGTCATCACCCTGTACAACCGCATCAAGAGGGAGCCCAATAAGTTTTTTGTG
CCTCGGACTGTGATGATTGGAGGGAAGGCTGCACCTGGGTACCACATGGCCAAGATGATC
ATCAGACTCGTCACAGCCATCGGGGATGTGGTCAACCATGACCCGGCAGTGGGTGACCGC
CTCCGTGTCATCTTCCTGGAGAACTACCGAGTCTCACTGGCCGAGAAAGTGATCCCAGCT
GCAGACCTCTCTGAGCAGATCTCCACTGCGGGCACTGAAGCCTCAGGCACCGGCAACATG
AAGTTCATGCTCAACGGGGCTCTGACCATTGGCACCATGGACGGGGCCAATGTGGAGATG
GCAGAAGAGGCGGGAGAGGAAAACTTCTTCATCTTTGGCATGCGGGTGGAGGATGTGGAT
AAGCTTGACCAAAGAGGGTACAATGCCCAGGAGTACTACGATCGCATTCCTGAGCTTCGG
CAGGTCATTGAGCAGCTGAGCAGTGGCTTCTTCTCCCCCAAACAACCCGACCTGTTCAAG
GACATTGTCAATATGCTCATGCACCATGACCGGTTTAAAGTCTTCGCAGATTATGAAGAC
TACATTAAATGCCAGGAGAAAGTCAGCGCCTGGTACAAGAACCCAAGAGAGTGGACGCGG
ATGGTGATCCGGAACATAGCCACTTCTGGCAAGTTCTCCAGTGACCGCACCATTGCCCAG
TATGCCCGGGAGATCTGGGGTGTGGAGCCTTCCCGCCAGCGCCTGCCAGCCCCGGATGAG
GCCATCTGA

# Drug_Target_4_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_4_General_References:
10382911	Andreu AL, Bruno C, Tamburino L, Gamez J, Shanske S, Cervera C, Navarro C, DiMauro S: A new mutation in the myophosphorylase gene (Asn684Tyr) in a Spanish patient with McArdle's disease. Neuromuscul Disord. 1999 May;9(3):171-3.
10382912	Rubio JC, Martin MA, Garcia A, Campos Y, Cabello A, Culebras JM, Arenas J: McArdle's disease associated with homozygosity for the missense mutation Gly204Ser of the myophosphorylase gene in a Spanish patient. Neuromuscul Disord. 1999 May;9(3):174-5.
10417800	Gamez J, Fernandez R, Bruno C, Andreu AL, Cervera C, Navarro C, Schwartz S, Dimauro S: A new mutation in the regulatory domain of the myophosphorylase gene affecting protein dimer contact. Muscle Nerve. 1999 Aug;22(8):1136-8.
10590419	Rubio JC, Martin MA, Campos Y, Auciello R, Cabello A, Arenas J: A missense mutation W797R in the myophosphorylase gene in a Spanish patient with McArdle's disease. Muscle Nerve. 2000 Jan;23(1):129-31.
10681080	Fernandez R, Navarro C, Andreu AL, Bruno C, Shanske S, Gamez J, Teijeira S, Hernandez I, Teijeiro A, Fernandez JM, Musumeci O, DiMauro S: A novel missense mutation (W797R) in the myophosphorylase gene in Spanish patients with McArdle disease. Arch Neurol. 2000 Feb;57(2):217-9.
10714589	Rubio JC, Martin MA, Campos Y, Cabello A, Arenas J: A missense mutation T487N in the myophosphorylase gene in a Spanish patient with McArdle's disease. Neuromuscul Disord. 2000 Feb;10(2):138-40.
10899452	Martin MA, Rubio JC, Campos Y, Ricoy JR, Cabello A, Arenas J: A homozygous missense mutation (A659D) in the myophosphorylase gene in a Spanish patient with McArdle's disease. Neuromuscul Disord. 2000 Aug;10(6):447-9.
11706962	Martin MA, Rubio JC, Buchbinder J, Fernandez-Hojas R, del Hoyo P, Teijeira S, Gamez J, Navarro C, Fernandez JM, Cabello A, Campos Y, Cervera C, Culebras JM, Andreu AL, Fletterick R, Arenas J: Molecular heterogeneity of myophosphorylase deficiency (McArdle's disease): a genotype-phenotype correlation study. Ann Neurol. 2001 Nov;50(5):574-81.
12031624	Bruno C, Lanzillo R, Biedi C, Iadicicco L, Minetti C, Santoro L: Two new mutations in the myophosphorylase gene in Italian patients with McArdle's disease. Neuromuscul Disord. 2002 Jun;12(5):498-500.
3447177	Burke J, Hwang P, Anderson L, Lebo R, Gorin F, Fletterick R: Intron/exon structure of the human gene for the muscle isozyme of glycogen phosphorylase. Proteins. 1987;2(3):177-87.
3466902	Gautron S, Daegelen D, Mennecier F, Dubocq D, Kahn A, Dreyfus JC: Molecular mechanisms of McArdle's disease (muscle glycogen phosphorylase deficiency). RNA and DNA analysis. J Clin Invest. 1987 Jan;79(1):275-81.
3840433	Hwang PK, See YP, Vincentini AM, Powers MA, Fletterick RJ, Crerar MM: Comparative sequence analysis of rat, rabbit, and human muscle glycogen phosphorylase cDNAs. Eur J Biochem. 1985 Oct 15;152(2):267-74.
7603523	Tsujino S, Shanske S, Nonaka I, DiMauro S: The molecular genetic basis of myophosphorylase deficiency (McArdle's disease). Muscle Nerve. 1995;3:S23-7.
8316268	Tsujino S, Shanske S, DiMauro S: Molecular genetic heterogeneity of myophosphorylase deficiency (McArdle's disease). N Engl J Med. 1993 Jul 22;329(4):241-5.
8535454	Tsujino S, Shanske S, Martinuzzi A, Heiman-Patterson T, DiMauro S: Two novel missense mutations (E654K, L396P) in Caucasian patients with myophosphorylase deficiency (McArdle's disease). Hum Mutat. 1995;6(3):276-7.
9506549	Vorgerd M, Kubisch C, Burwinkel B, Reichmann H, Mortier W, Tettenborn B, Pongratz D, Lindemuth R, Tegenthoff M, Malin JP, Kilimann MW: Mutation analysis in myophosphorylase deficiency (McArdle's disease). Ann Neurol. 1998 Mar;43(3):326-31.

# Drug_Target_4_HGNC_ID:
HGNC:9726

# Drug_Target_4_HPRD_ID:
01986

# Drug_Target_4_ID:
1152

# Drug_Target_4_Locus:
11q12-q13.2

# Drug_Target_4_Molecular_Weight:
97093

# Drug_Target_4_Name:
Glycogen phosphorylase, muscle form

# Drug_Target_4_Number_of_Residues:
842

# Drug_Target_4_PDB_ID:
1XL1

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00343	Phosphorylase

# Drug_Target_4_Protein_Sequence:
>Glycogen phosphorylase, muscle form
MSRPLSDQEKRKQISVRGLAGVENVTELKKNFNRHLHFTLVKDRNVATPRDYYFALAHTV
RDHLVGRWIRTQQHYYEKDPKRIYYLSLEFYMGRTLQNTMVNLALENACDEATYQLGLDM
EELEEIEEDAGLGNGGLGRLAACFLDSMATLGLAAYGYGIRYEFGIFNQKISGGWQMEEA
DDWLRYGNPWEKARPEFTLPVHFYGHVEHTSQGAKWVDTQVVLAMPYDTPVPGYRNNVVN
TMRLWSAKAPNDFNLKDFNVGGYIQAVLDRNLAENISRVLYPNDNFFEGKELRLKQEYFV
VAATLQDIIRRFKSSKFGCRDPVRTNFDAFPDKVAIQLNDTHPSLAIPELMRILVDLERM
DWDKAWDVTVRTCAYTNHTVLPEALERWPVHLLETLLPRHLQIIYEINQRFLNRVAAAFP
GDVDRLRRMSLVEEGAVKRINMAHLCIAGSHAVNGVARIHSEILKKTIFKDFYELEPHKF
QNKTNGITPRRWLVLCNPGLAEVIAERIGEDFISDLDQLRKLLSFVDDEAFIRDVAKVKQ
ENKLKFAAYLEREYKVHINPNSLFDIQVKRIHEYKRQLLNCLHVITLYNRIKREPNKFFV
PRTVMIGGKAAPGYHMAKMIIRLVTAIGDVVNHDPAVGDRLRVIFLENYRVSLAEKVIPA
ADLSEQISTAGTEASGTGNMKFMLNGALTIGTMDGANVEMAEEAGEENFFIFGMRVEDVD
KLDQRGYNAQEYYDRIPELRQVIEQLSSGFFSPKQPDLFKDIVNMLMHHDRFKVFADYED
YIKCQEKVSALYKNPREWTRMVIRNIATSGKFSSDRTIAQYAREIWGVEPSRQRLPAPDE
AI

# Drug_Target_4_Reaction:
(1,4-alpha-D-glucosyl)n + phosphate = (1,4-alpha-D-glucosyl)n-1 + alpha-D-glucose 1-phosphate

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties

# Drug_Target_4_SwissProt_ID:
P11217

# Drug_Target_4_SwissProt_Name:
PYGM_HUMAN

# Drug_Target_4_Synonyms:
EC 2.4.1.1
Myophosphorylase

# Drug_Target_4_Theoretical_pI:
7.03

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
X69160

# Drug_Target_5_GenBank_ID_Protein:
577561

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
otsA

# Drug_Target_5_Gene_Sequence:
>1425 bp
ATGAGTCGTTTAGTCGTAGTATCTAACCGGATTGCACCACCAGACGAGCACGCCGCCAGT
GCCGGTGGCCTTGCCGTTGGCATACTGGGGGCACTGAAAGCCGCAGGCGGACTGTGGTTT
GGCTGGAGTGGTGAAACAGGGAATGAGGATCAGCCGCTAAAAAAGGTGAAAAAAGGTAAC
ATTACGTGGGCCTCTTTTAACCTCAGCGAACAGGACCTTGACGAATACTACAACCAATTC
TCCAATGCCGTTCTCTGGCCCGCTTTTCATTATCGGCTCGATCTGGTGCAATTTCAGCGT
CCTGCCTGGGACGGCTATCTACGCGTAAATGCGTTGCTGGCAGATAAATTACTGCCGCTG
TTGCAAGACGATGACATTATCTGGATCCACGATTATCACCTGTTGCCATTTGCGCATGAA
TTACGCAAACGGGGAGTGAATAATCGCATTGGTTTCTTTCTGCATATTCCTTTCCCGACA
CCGGAAATCTTCAACGCGCTGCCGACATATGACACCTTGCTTGAACAGCTTTGTGATTAT
GATTTGCTGGGTTTCCAGACAGAAAACGATCGTCTGGCGTTCCTGGATTGTCTTTCTAAC
CTGACCCGCGTCACGACACGTAGCGCAAAAAGCCATACAGCCTGGGGCAAAGCATTTCGA
ACAGAAGTCTACCCGATCGGCATTGAACCGAAAGAAATAGCCAAACAGGCTGCCGGGCCA
CTGCCGCCAAAACTGGCGCAACTTAAAGCGGAACTGAAAAACGTACAAAATATCTTTTCT
GTCGAACGGCTGGATTATTCCAAAGGTTTGCCAGAGCGTTTTCTCGCCTATGAAGCGTTG
CTGGAAAAATATCCGCAGCATCATGGTAAAATTCGTTATACCCAGATTGCACCAACGTCG
CGTGGTGATGTGCAAGCCTATCAGGATATTCGTCATCAGCTCGAAAATGAAGCTGGACGA
ATTAATGGTAAATACGGGCAATTAGGCTGGACGCCGCTTTATTATTTGAATCAGCATTTT
GACCGTAAATTACTGATGAAAATATTCCGCTACTCTGACGTGGGCTTAGTGACGCCACTG
CGTGACGGGATGAACCTGGTAGCAAAAGAGTATGTTGCTGCTCAGGACCCAGCCAATCCG
GGCGTTCTTGTTCTTTCGCAATTTGCGGGAGCGGCAAACGAGTTAACGTCGGCGTTAATT
GTTAACCCCTACGATCGTGACGAAGTTGCAGCTGCGCTGGATCGTGCATTGACTATGTCG
CTGGCGGAACGTATTTCCCGTCATGCAGAAATGCTGGACGTTATCGTGAAAAACGATATT
AACCACTGGCAGGAGTGCTTCATTAGCGACCTAAAGCAGATAGTTCCGCGAAGCGCGGAA
AGCCAGCAGCGCGATAAAGTTGCTACCTTTCCAAAGCTTGCGTAG

# Drug_Target_5_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_5_General_References:
8045430	Kaasen I, McDougall J, Strom AR: Analysis of the otsBA operon for osmoregulatory trehalose synthesis in Escherichia coli and homology of the OtsA and OtsB proteins to the yeast trehalose-6-phosphate synthase/phosphatase complex. Gene. 1994 Jul 22;145(1):9-15.
9097040	Itoh T, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Kasai H, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Seki Y, Horiuchi T, et al.: A 460-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 40.1-50.0 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):379-92.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
2439

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
53612

# Drug_Target_5_Name:
Alpha,alpha-trehalose-phosphate synthase [UDP-forming]

# Drug_Target_5_Number_of_Residues:
474

# Drug_Target_5_PDB_ID:
1UQU

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00982	Glyco_transf_20

# Drug_Target_5_Protein_Sequence:
>Alpha,alpha-trehalose-phosphate synthase [UDP-forming]
MSRLVVVSNRIAPPDEHAASAGGLAVGILGALKAAGGLWFGWSGETGNEDQPLKKVKKGN
ITWASFNLSEQDLDEYYNQFSNAVLWPAFHYRLDLVQFQRPAWDGYLRVNALLADKLLPL
LQDDDIIWIHDYHLLPFAHELRKRGVNNRIGFFLHIPFPTPEIFNALPTYDTLLEQLCDY
DLLGFQTENDRLAFLDCLSNLTRVTTRSAKSHTAWGKAFRTEVYPIGIEPKEIAKQAAGP
LPPKLAQLKAELKNVQNIFSVERLDYSKGLPERFLAYEALLEKYPQHHGKIRYTQIAPTS
RGDVQAYQDIRHQLENEAGRINGKYGQLGWTPLYYLNQHFDRKLLMKIFRYSDVGLVTPL
RDGMNLVAKEYVAAQDPANPGVLVLSQFAGAANELTSALIVNPYDRDEVAAALDRALTMS
LAERISRHAEMLDVIVKNDINHWQECFISDLKQIVPRSAESQQRDKVATFPKLA

# Drug_Target_5_Reaction:
UDP-glucose + D-glucose 6-phosphate = UDP + alpha,alpha-trehalose 6-phosphate

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
UDP-glucose + D-glucose 6-phosphate = UDP + alpha,alpha-trehalose 6-phosphate

# Drug_Target_5_SwissProt_ID:
P31677

# Drug_Target_5_SwissProt_Name:
OTSA_ECOLI

# Drug_Target_5_Synonyms:
EC 2.4.1.15
Trehalose-6-phosphate synthase
UDP-glucose-glucosephosphate glucosyltransferase

# Drug_Target_5_Theoretical_pI:
6.85

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Cytoplasm

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
X01631

# Drug_Target_6_GenBank_ID_Protein:
43268

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
glmS

# Drug_Target_6_Gene_Sequence:
>1830 bp
ATGTGTGGAATTGTTGGCGCGATCGCGCAACGTGATGTAGCAGAAATCCTTCTTGAAGGT
TTACGTCGTCTGGAATACCGCGGATATGACTCTGCCGGTCTGGCCGTTGTTGATGCAGAA
GGTCATATGACCCGCCTGCGTCGCCTCGGTAAAGTCCAGATGCTGGCACAGGCAGCGGAA
GAACATCCTCTGCATGGCGGCACTGGTATTGCTCACACTCGCTGGGCGACCCACGGTGAA
CCTTCAGAAGTGAATGCGCATCCGCATGTTTCTGAACACATTGTGGTGGTGCATAACGGC
ATCATCGAAAACCATGAACCGCTGCGTGAAGAGCTAAAAGCGCGTGGCTATACCTTCGTT
TCTGAAACCGACACCGAAGTGATTGCCCATCTGGTGAACTGGGAGCTGAAACAAGGCGGG
ACTCTGCGTGAGGCCGTTCTGCGTGCTATCCCGCAGCTGCGTGGTGCGTACGGTACAGTG
ATCATGGACTCCCGTCACCCGGATACCCTGCTGGCGGCACGTTCTGGTAGTCCGCTGGTG
ATTGGCCTGGGGATGGGCGAAAACTTTATCGCTTCTGACCAGCTGGCGCTGTTGCCGGTG
ACCCGTCGCTTTATCTTCCTTGAAGAGGGCGATATTGCGGAAATCACTCGCCGTTCGGTA
AACATCTTCGATAAAACTGGCGCGGAAGTAAAACGTCAGGATATCGAATCCAATCTGCAA
TATGACGCGGGCGATAAAGGCATTTACCGTCACTACATGCAGAAAGAGATCTACGAACAG
CCGAACGCGATCAAAAACACCCTTACCGGACGCATCAGCCACGGTCAGGTTGATTTAAGC
GAGCTGGGACCGAACGCCGACGAACTGCTGTCGAAGGTTGAGCATATTCAGATCCTCGCC
TGTGGTACTTCTTATAACTCCGGTATGGTTTCCCGCTACTGGTTTGAATCGCTAGCAGGT
ATTCCGTGCGACGTCGAAATCGCCTCTGAATTCCGCTATCGCAAATCTGCCGTGCGTCGT
AACAGCCTGATGATCACCTTGTCACAGTCTGGCGAAACCGCGGATACCCTGGCTGGCCTG
CGTCTGTCGAAAGAGCTGGGTTACCTTGGTTCACTGGCAATCTGTAACGTTCCGGGTTCT
TCTCTGGTGCGCGAATCCGATCTGGCGCTAATGACCAACGCGGGTACAGAAATCGGCGTG
GCATCCACTAAAGCATTCACCACTCAGTTAACTGTGCTGTTGATGCTGGTGGCGAACGTG
TCTCGCCTGAAAGGTCTGGATGCCTCCATTGAACATGACATCGTGCATGGTCTGCAGGCG
CTGCCGAGCCGTATTGAGCAGATGCTGTCTCAGGACAAACGCATTGAAGCGCTGGCAGAA
GATTTCTCTGACAAACATCACGCGCTGTTCCTGGGCCGTGGCGATCAGTACCCAATCGCG
CTGGAAGGCGCATTGAAGTTGAAAGAGATCTCTTACATTCACGCTGAAGCCTACGCTGCT
GGCGAACTGAAACACGGTCCGCTGGCGCTAATTGATGCCGATATGCCGGTTATTGTTGTT
GCACCGAACAACGAATTGCTGGAAAAACTGAAATCCAACATTGAAGAAGTTCGCGCGCGT
GGCGGTCAGTTGTATGTCTTCGCCGATCAGGATGCGGGTTTTGTAAGTAGCGATAACATG
CACATCATCGAGATGCCGCATGTGGAAGAGGTGATTGCACCGATCTTCTACACCGTTCCG
CTGCAGCTGCTGGCTTACCATGTCGCGCTGATCAAAGGCACCGACGTTGACCAGCCGCGT
AACCTGGCAAAATCGGTTACGGTTGAGTAA

# Drug_Target_6_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_6_General_References:
10091662	Teplyakov A, Obmolova G, Badet-Denisot MA, Badet B: The mechanism of sugar phosphate isomerization by glucosamine 6-phosphate synthase. Protein Sci. 1999 Mar;8(3):596-602.
1915361	Golinelli-Pimpaneau B, Badet B: Possible involvement of Lys603 from Escherichia coli glucosamine-6-phosphate synthase in the binding of its substrate fructose 6-phosphate. Eur J Biochem. 1991 Oct 1;201(1):175-82.
2826397	McKown RL, Orle KA, Chen T, Craig NL: Sequence requirements of Escherichia coli attTn7, a specific site of transposon Tn7 insertion. J Bacteriol. 1988 Jan;170(1):352-8.
3010949	Gay NJ, Tybulewicz VL, Walker JE: Insertion of transposon Tn7 into the Escherichia coli glmS transcriptional terminator. Biochem J. 1986 Feb 15;234(1):111-7.
3134953	Dutka-Malen S, Mazodier P, Badet B: Molecular cloning and overexpression of the glucosamine synthetase gene from Escherichia coli. Biochimie. 1988 Feb;70(2):287-90.
6283361	Lichtenstein C, Brenner S: Unique insertion site of Tn7 in the E. coli chromosome. Nature. 1982 Jun 17;297(5867):601-3.
6395859	Walker JE, Gay NJ, Saraste M, Eberle AN: DNA sequence around the Escherichia coli unc operon. Completion of the sequence of a 17 kilobase segment containing asnA, oriC, unc, glmS and phoS. Biochem J. 1984 Dec 15;224(3):799-815.
7686882	Burland V, Plunkett G 3rd, Daniels DL, Blattner FR: DNA sequence and analysis of 136 kilobases of the Escherichia coli genome: organizational symmetry around the origin of replication. Genomics. 1993 Jun;16(3):551-61.
8805567	Isupov MN, Obmolova G, Butterworth S, Badet-Denisot MA, Badet B, Polikarpov I, Littlechild JA, Teplyakov A: Substrate binding is required for assembly of the active conformation of the catalytic site in Ntn amidotransferases: evidence from the 1.8 A crystal structure of the glutaminase domain of glucosamine 6-phosphate synthase. Structure. 1996 Jul 15;4(7):801-10.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9739095	Teplyakov A, Obmolova G, Badet-Denisot MA, Badet B, Polikarpov I: Involvement of the C terminus in intramolecular nitrogen channeling in glucosamine 6-phosphate synthase: evidence from a 1.6 A crystal structure of the isomerase domain. Structure. 1998 Aug 15;6(8):1047-55.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
2597

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
66895

# Drug_Target_6_Name:
Glucosamine--fructose-6-phosphate aminotransferase [isomerizing]

# Drug_Target_6_Number_of_Residues:
609

# Drug_Target_6_PDB_ID:
1JXA

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00310	GATase_2
PF01380	SIS

# Drug_Target_6_Protein_Sequence:
>Glucosamine--fructose-6-phosphate aminotransferase [isomerizing]
MCGIVGAIAQRDVAEILLEGLRRLEYRGYDSAGLAVVDAEGHMTRLRRLGKVQMLAQAAE
EHPLHGGTGIAHTRWATHGEPSEVNAHPHVSEHIVVVHNGIIENHEPLREELKARGYTFV
SETDTEVIAHLVNWELKQGGTLREAVLRAIPQLRGAYGTVIMDSRHPDTLLAARSGSPLV
IGLGMGENFIASDQLALLPVTRRFIFLEEGDIAEITRRSVNIFDKTGAEVKRQDIESNLQ
YDAGDKGIYRHYMQKEIYEQPNAIKNTLTGRISHGQVDLSELGPNADELLSKVEHIQILA
CGTSYNSGMVSRYWFESLAGIPCDVEIASEFRYRKSAVRRNSLMITLSQSGETADTLAGL
RLSKELGYLGSLAICNVPGSSLVRESDLALMTNAGTEIGVASTKAFTTQLTVLLMLVAKL
SRLKGLDASIEHDIVHGLQALPSRIEQMLSQDKRIEALAEDFSDKHHALFLGRGDQYPIA
LEGALKLKEISYIHAEAYAAGELKHGPLALIDADMPVIVVAPNNELLEKLKSNIEEVRAR
GGQLYVFADQDAGFVSSDNMHIIEMPHVEEVIAPIFYTVPLQLLAYHVALIKGTDVDQPR
NLAKSVTVE

# Drug_Target_6_Reaction:
L-glutamine + D-fructose 6-phosphate = L-glutamate + D-glucosamine 6-phosphate

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Catalyzes the first step in hexosamine metabolism, converting fructose-6P into glucosamine-6P using glutamine as a nitrogen source

# Drug_Target_6_SwissProt_ID:
P17169

# Drug_Target_6_SwissProt_Name:
GLMS_ECOLI

# Drug_Target_6_Synonyms:
D-fructose-6- phosphate amidotransferase
EC 2.6.1.16
GFAT
Glucosamine-6-phosphate synthase
Hexosephosphate aminotransferase
L-glutamine-D-fructose-6-phosphate amidotransferase

# Drug_Target_6_Theoretical_pI:
5.74

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Cytoplasmic

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
AE000512

# Drug_Target_7_GenBank_ID_Protein:
4981838

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
bglT

# Drug_Target_7_Gene_Sequence:
>1248 bp
ATGAGAATTGCGGTGATAGGTGGGGGAAGCAGCTACACCCCGGAGCTGGTGAAGGGACTT
CTCGACATTTCCGAGGATGTTCGCATCGACGAGGTGATCTTCTACGACATCGACGAAGAA
AAGCAGAAAATCGTCGTTGATTTCGTGAAGAGACTCGTCAAAGACAGGTTCAAGGTGCTC
ATAAGCGACACCTTCGAGGGTGCTGTCGTGGACGCGAAGTACGTGATCTTTCAGTTCAGA
CCCGGCGGACTCAAAGGTAGAGAAAACGACGAAGGCATTCCGCTGAAGTACGGTCTCATA
GGTCAAGAGACAACGGGGGTTGGGGGATTTTCAGCGGCTTTGAGGGCGTTTCCCATAGTA
GAAGAGTACGTTGATACCGTGAGAAAAACATCGAACGCGACCATCGTAAACTTCACCAAC
CCATCCGGCCACATTACGGAGTTCGTGAGAAACTACCTCGAATACGAAAAATTCATAGGT
CTCTGCAACGTTCCCATAAACTTCATCCGGGAGATCGCAGAGATGTTCTCAGCAAGGCTC
GAAGACGTGTTCCTGAAGTACTACGGCCTCAACCATCTGAGCTTCATAGAGAAGGTCTTC
GTAAAAGGTGAAGACGTGACGGAAAAGGTTTTCGAGAACCTGAAGCTGAAGCTCTCCAAC
ATACCAGACGAGGATTTCCCGACGTGGTTCTACGACTCGGTGAGACTCATTGTGAATCCT
TACCTGAGGTACTACCTGATGGAGAAGAAGATGTTCAAAAAGATCTCCACACACGAGCTC
AGAGCAAGGGAAGTGATGAAGATAGAGAAAGAACTCTTCGAGAAGTACAGAACCGCTGTC
GAGATACCGGAGGAACTCACAAAACGCGGTGGCAGCATGTATTCCACAGCGGCAGCTCAC
CTGATAAGAGACCTCGAAACCGACGAAGGAAAGATACACATCGTGAACACGAGAAACAAC
GGCTCGATCGAGAACCTCCCGGATGATTACGTTCTGGAGATCCCGTGTTATGTGAGATCC
GGCAGGGTTCACACGCTCTCGCAGGGAAAAGGAGATCACTTTGCTCTTTCTTTCATCCAC
GCGGTGAAGATGTACGAGCGACTCACAATAGAAGCGTATCTGAAGAGATCGAAAAAACTC
GCTCTAAAGGCTTTGCTTTCCCATCCTCTCGGACCCGATGTGGAGGACGCAAAAGACCTT
CTCGAAGAGATACTGGAGGCGAACAGAGAATACGTGAAACTGGGGTGA

# Drug_Target_7_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_7_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
2538

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
47627

# Drug_Target_7_Name:
6-phospho-beta-glucosidase bglT

# Drug_Target_7_Number_of_Residues:
415

# Drug_Target_7_PDB_ID:
1UP7

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF02056	Glyco_hydro_4

# Drug_Target_7_Protein_Sequence:
>6-phospho-beta-glucosidase bglT
MRIAVIGGGSSYTPELVKGLLDISEDVRIDEVIFYDIDEEKQKIVVDFVKRLVKDRFKVL
ISDTFEGAVVDAKYVIFQFRPGGLKGRENDEGIPLKYGLIGQETTGVGGFSAALRAFPIV
EEYVDTVRKTSNATIVNFTNPSGHITEFVRNYLEYEKFIGLCNVPINFIREIAEMFSARL
EDVFLKYYGLNHLSFIEKVFVKGEDVTEKVFENLKLKLSNIPDEDFPTWFYDSVRLIVNP
YLRYYLMEKKMFKKISTHELRAREVMKIEKELFEKYRTAVEIPEELTKRGGSMYSTAAAH
LIRDLETDEGKIHIVNTRNNGSIENLPDDYVLEIPCYVRSGRVHTLSQGKGDHFALSFIH
AVKMYERLTIEAYLKRSKKLALKALLSHPLGPDVEDAKDLLEEILEANREYVKLG

# Drug_Target_7_Reaction:
6-phospho-beta-D-glucosyl-(1,4)-D-glucose + H2O = D-glucose + D-glucose 6-phosphate

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Hydrolyzes cellobiose 6'-phosphate into glucose 6- phosphate (Glc6P) and glucose

# Drug_Target_7_SwissProt_ID:
Q9X108

# Drug_Target_7_SwissProt_Name:
BGLT_THEMA

# Drug_Target_7_Synonyms:
EC 3.2.1.86

# Drug_Target_7_Theoretical_pI:
5.92

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Cytoplasm

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
GPI

# Drug_Target_8_GenBank_ID_Gene:
K03515

# Drug_Target_8_GenBank_ID_Protein:
189238

# Drug_Target_8_GeneCard_ID:
GPI

# Drug_Target_8_Gene_Name:
GPI

# Drug_Target_8_Gene_Sequence:
>1677 bp
ATGGCCGCTCTCACCCGGGACCCCCAGTTCCAGAAGCTGCAGCAATGGTACCGCGAGCAC
CGCTCCGAGCTGAACCTGCGCCGCCTCTTCGATGCCAACAAGGACCGCTTCAACCACTTC
AGCTTGACCCTCAACACCAACCATGGGCATATCCTGGTGGATTACTCCAAGAACCTGGTG
ACGGAGGACGTGATGCGGATGCTGGTGGACTTGGCCAAGTCCAGGGGCGTGGAGGCCGCC
CGGGAGCGGATGTTCAATGGTGAGAAGATCAACTACACCGAGGGTCGAGCCGTGCTGCAC
GTGGCTCTGCGGAACCGGTCAAACACACCCATCCTGGTAGACGGCAAGGATGTGATGCCA
GAGGTCAACAAGGTTCTGGACAAGATGAAGTCTTTCTGCCAGCGTGTCCGGAGCGGTGAC
TGGAAGGGGTACACAGGCAAGACCATCACGGACGTCATCAACATTGGCATTGTCGGCTCC
GACCTGGGACCCCTCATGGTGACTGAAGCCCTTAAGCCATACTCTTCAGGAGGTCCCCGC
GTCTGGTATGTCTCCAACATTGATGGAACTCACATTGCCAAAACCCTGGCCCAGCTGAAC
CCGGAGTCCTCCCTGTTCATCATTGCCTCCAAGACCTTTACTACCCAGGAGACCATCACG
AATGCAGAGACGGCGAAGGAGTGGTTTCTCCAGGCGGCCAAGGATCCTTCTGCAGTGGCG
AAGCACTTTGTTGCCCTGTCTACTAACACAACCAAAGTGAAGGAGTTTGGAATTGACCCT
CAAAACATGTTCGAGTTCTGGGATTGGGTGGGAGGACGCTACTCGCTGTGGTCGGCCATC
GGACTCTCCATTGCCCTGCACGTGGGTTTTGACAACTTCGAGCAGCTGCTCTCGGGGGCT
CACTGGATGGACCAGCACTTCCGCACGACGCCCCTGGAGAAGAACGCCCCCGTCTTGCTG
GCCCTGCTGGGTATCTGGTACATCAACTGCTTTGGGTGTGAGACACACGCCATGCTGCCC
TATGACCAGTACCTGCACCGCTTTGCTGCGTACTTCCAGCAGGGCGACATGGAGTCCAAT
GGGAAATACATCACCAAATCTGGAACCCGTGTGGACCACCAGACAGGCCCCATTGTGTGG
GGGGAGCCAGGGACCAATGGCCAGCATGCTTTTTACCAGCTCATCCACCAAGGCACCAAG
ATGATACCCTGTGACTTCCTCATCCCGGTCCAGACCCAGCACCCCATACGGAAGGGTCTG
CATCACAAGATCCTCCTGGCCAACTTCTTGGCCCAGACAGAGGCCCTGATGAGGGGAAAA
TCGACGGAGGAGGCCCGAAAGGAGCTCCAGGCTGCGGGCAAGAGTCCAGAGGACCTTGAG
AGGCTGCTGCCACATAAGGTCTTTGAAGGAAATCGCCCAACCAACTCTATTGTGTTCACC
AAGCTCACACCATTCATGCTTGGAGCCTTGGTCGCCATGTATGAGCACAAGATCTTCGTT
CAGGGCATCATCTGGGACATCAACAGCTTTGACCAGTGGGGAGTGGAGCTGGGAAAGCAG
CTGGCTAAGAAAATAGAGCCTGAGCTTGATGGCAGTGCTCAAGTGACCTCTCACGACGCT
TCTACCAATGGGCTCATCAACTTCATCAAGCAGCAGCGCGAGGCCAGAGTCCAATAA

# Drug_Target_8_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_8_General_References:
10727272	Yakirevich E, Naot Y: Cloning of a glucose phosphate isomerase/neuroleukin-like sperm antigen involved in sperm agglutination. Biol Reprod. 2000 Apr;62(4):1016-23.
2387591	Walker JI, Faik P, Morgan MJ: Characterization of the 5' end of the gene for human glucose phosphate isomerase (GPI). Genomics. 1990 Aug;7(4):638-43.
3352745	Faik P, Walker JI, Redmill AA, Morgan MJ: Mouse glucose-6-phosphate isomerase and neuroleukin have identical 3' sequences. Nature. 1988 Mar 31;332(6163):455-7.
7989588	Xu W, Beutler E: The characterization of gene mutations for human glucose phosphate isomerase deficiency associated with chronic hemolytic anemia. J Clin Invest. 1994 Dec;94(6):2326-9.
8499925	Walker JI, Layton DM, Bellingham AJ, Morgan MJ, Faik P: DNA sequence abnormalities in human glucose 6-phosphate isomerase deficiency. Hum Mol Genet. 1993 Mar;2(3):327-9.
8822952	Baronciani L, Zanella A, Bianchi P, Zappa M, Alfinito F, Iolascon A, Tannoia N, Beutler E, Sirchia G: Study of the molecular defects in glucose phosphate isomerase-deficient patients affected by chronic hemolytic anemia. Blood. 1996 Sep 15;88(6):2306-10.
8822954	Kanno H, Fujii H, Hirono A, Ishida Y, Ohga S, Fukumoto Y, Matsuzawa K, Ogawa S, Miwa S: Molecular analysis of glucose phosphate isomerase deficiency associated with hereditary hemolytic anemia. Blood. 1996 Sep 15;88(6):2321-5.
9446754	Beutler E, West C, Britton HA, Harris J, Forman L: Glucosephosphate isomerase (GPI) deficiency mutations associated with hereditary nonspherocytic hemolytic anemia (HNSHA). Blood Cells Mol Dis. 1997 Dec;23(3):402-9.
9856489	Kugler W, Breme K, Laspe P, Muirhead H, Davies C, Winkler H, Schroter W, Lakomek M: Molecular basis of neurological dysfunction coupled with haemolytic anaemia in human glucose-6-phosphate isomerase (GPI) deficiency. Hum Genet. 1998 Oct;103(4):450-4.

# Drug_Target_8_HGNC_ID:
HGNC:4458

# Drug_Target_8_HPRD_ID:
01394

# Drug_Target_8_ID:
2206

# Drug_Target_8_Locus:
19q13.1

# Drug_Target_8_Molecular_Weight:
63148

# Drug_Target_8_Name:
Glucose-6-phosphate isomerase

# Drug_Target_8_Number_of_Residues:
558

# Drug_Target_8_PDB_ID:
1NUH

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00342	PGI

# Drug_Target_8_Protein_Sequence:
>Glucose-6-phosphate isomerase
MAALTRDPQFQKLQQWYREHRSELNLRRLFDANKDRFNHFSLTLNTNHGHILVDYSKNLV
TEDVMRMLVDLAKSRGVEAARERMFNGEKINYTEGRAVLHVALRNRSNTPILVDGKDVMP
EVNKVLDKMKSFCQRVRSGDWKGYTGKTITDVINIGIGGSDLGPLMVTEALKPYSSGGPR
VWYVSNIDGTHIAKTLAQLNPESSLFIIASKTFTTQETITNAETAKEWFLQAAKDPSAVA
KHFVALSTNTTKVKEFGIDPQNMFEFWDWVGGRYSLWSAIGLSIALHVGFDNFEQLLSGA
HWMDQHFRTTPLEKNAPVLLALLGIWYINCFGCETHAMLPYDQYLHRFAAYFQQGDMESN
GKYITKSGTRVDHQTGPIVWGEPGTNGQHAFYQLIHQGTKMIPCDFLIPVQTQHPIRKGL
HHKILLANFLAQTEALMRGKSTEEARKELQAAGKSPEDLERLLPHKVFEGNRPTNSIVFT
KLTPFMLGALVAMYEHKIFVQGIIWDINSFDQWGVELGKQLAKKIEPELDGSAQVTSHDA
STNGLINFIKQQREARVQ

# Drug_Target_8_Reaction:
D-glucose 6-phosphate = D-fructose 6-phosphate

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Neuroleukin is a neurotrophic factor for spinal and sensory neurons

# Drug_Target_8_SwissProt_ID:
P06744

# Drug_Target_8_SwissProt_Name:
G6PI_HUMAN

# Drug_Target_8_Synonyms:
EC 5.3.1.9
GPI
NLK
Neuroleukin
PGI
PHI
Phosphoglucose isomerase
Phosphohexose isomerase
SA-36
Sperm antigen 36

# Drug_Target_8_Theoretical_pI:
8.55

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Cytoplasm

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
AKR1B1

# Drug_Target_9_GenBank_ID_Gene:
J04795

# Drug_Target_9_GenBank_ID_Protein:
178487

# Drug_Target_9_GeneCard_ID:
AKR1B1

# Drug_Target_9_Gene_Name:
AKR1B1

# Drug_Target_9_Gene_Sequence:
>951 bp
ATGGCAAGCCGTCTCCTGCTCAACAACGGCGCCAAGATGCCCATCCTGGGGTTGGGTACC
TGGAAGTCCCCTCCAGGGCAGGTGACTGAGGCCGTGAAGGTGGCCATTGACGTCGGGTAC
CGCCACATCGACTGTGCCCATGTGTACCAGAATGAGAATGAGGTGGGGGTGGCCATTCAG
GAGAAGCTCAGGGAGCAGGTGGTGAAGCGTGAGGAGCTCTTCATCGTCAGCAAGCTGTGG
TGCACGTACCATGAGAAGGGCCTGGTGAAAGGAGCCTGCCAGAAGACACTCAGCGACCTG
AAGCTGGACTACCTGGACCTCTACCTTATTCACTGGCCGACTGGCTTTAAGCCTGGGAAG
GAATTTTTCCCATTGGATGAGTCGGGCAATGTGGTTCCCAGTGACACCAACATTCTGGAC
ACGTGGGCGGCCATGGAAGAGCTGGTGGATGAAGGGCTGGTGAAAGCTATTGGCATCTCC
AACTTCAACCATCTCCAGGTGGAGATGATCTTAAACAAACCTGGCTTGAAGTATAAGCCT
GCAGTTAACCAGATTGAGTGCCACCCATATCTCACTCAGGAGAAGTTAATCCAGTACTGC
CAGTCCAAAGGCATCGTGGTGACCGCCTACAGCCCCCTCGGCTCTCCTGACAGGCCCTGG
GCCAAGCCCGAGGACCCTTCTCTCCTGGAGGATCCCAGGATCAAGGCGATCGCAGCCAAG
CACAATAAAACTACAGCCCAGGTCCTGATCCGGTTCCCCATGCAGAGGAACTTGGTGGTG
ATCCCCAAGTCTGTGACACCAGAACGCATTGCTGAGAACTTTAAGGTCTTTGACTTTGAA
CTGAGCAGCCAGGATATGACCACCTTACTCAGCTACAACAGGAACTGGAGGGTCTGTGCC
TTGTTGAGCTGTACCTCCCACAAGGATTACCCCTTCCATGAAGAGTTTTGA

# Drug_Target_9_General_Function:
Involved in oxidoreductase activity

# Drug_Target_9_General_References:
1447221	Borhani DW, Harter TM, Petrash JM: The crystal structure of the aldose reductase.NADPH binary complex. J Biol Chem. 1992 Dec 5;267(34):24841-7.
1621098	Wilson DK, Bohren KM, Gabbay KH, Quiocho FA: An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science. 1992 Jul 3;257(5066):81-4.
1901857	Graham A, Brown L, Hedge PJ, Gammack AJ, Markham AF: Structure of the human aldose reductase gene. J Biol Chem. 1991 Apr 15;266(11):6872-7.
2111143	Grundmann U, Bohn H, Obermeier R, Amann E: Cloning and prokaryotic expression of a biologically active human placental aldose reductase. DNA Cell Biol. 1990 Apr;9(3):149-57.
2112546	Nishimura C, Matsuura Y, Kokai Y, Akera T, Carper D, Morjana N, Lyons C, Flynn TG: Cloning and expression of human aldose reductase. J Biol Chem. 1990 Jun 15;265(17):9788-92.
2492527	Morjana NA, Lyons C, Flynn TG: Aldose reductase from human psoas muscle. Affinity labeling of an active site lysine by pyridoxal 5'-phosphate and pyridoxal 5'-diphospho-5'-adenosine. J Biol Chem. 1989 Feb 15;264(5):2912-9.
2498333	Bohren KM, Bullock B, Wermuth B, Gabbay KH: The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J Biol Chem. 1989 Jun 5;264(16):9547-51.
2504709	Chung S, LaMendola J: Cloning and sequence determination of human placental aldose reductase gene. J Biol Chem. 1989 Sep 5;264(25):14775-7.
2510130	Graham A, Hedge PJ, Powell SJ, Riley J, Brown L, Gammack A, Carey F, Markham AF: Nucleotide sequence of cDNA for human aldose reductase. Nucleic Acids Res. 1989 Oct 25;17(20):8368.
8234324	Wilson DK, Tarle I, Petrash JM, Quiocho FA: Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9847-51.
8245005	Tarle I, Borhani DW, Wilson DK, Quiocho FA, Petrash JM: Probing the active site of human aldose reductase. Site-directed mutagenesis of Asp-43, Tyr-48, Lys-77, and His-110. J Biol Chem. 1993 Dec 5;268(34):25687-93.
8281941	Jaquinod M, Potier N, Klarskov K, Reymann JM, Sorokine O, Kieffer S, Barth P, Andriantomanga V, Biellmann JF, Van Dorsselaer A: Sequence of pig lens aldose reductase and electrospray mass spectrometry of non-covalent and covalent complexes. Eur J Biochem. 1993 Dec 15;218(3):893-903.
8343525	Liu SQ, Bhatnagar A, Ansari NH, Srivastava SK: Identification of the reactive cysteine residue in human placenta aldose reductase. Biochim Biophys Acta. 1993 Aug 7;1164(3):268-72.
8435445	Ferraretto A, Negri A, Giuliani A, De Grada L, Fuhrman Conti AM, Ronchi S: Aldose reductase is involved in long-term adaptation of EUE cells to hyperosmotic stress. Biochim Biophys Acta. 1993 Feb 17;1175(3):283-8.
9195951	Ko BC, Ruepp B, Bohren KM, Gabbay KH, Chung SS: Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene. J Biol Chem. 1997 Jun 27;272(26):16431-7.
9405046	Harrison DH, Bohren KM, Petsko GA, Ringe D, Gabbay KH: The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant. Biochemistry. 1997 Dec 23;36(51):16134-40.

# Drug_Target_9_HGNC_ID:
HGNC:381

# Drug_Target_9_HPRD_ID:
00071

# Drug_Target_9_ID:
822

# Drug_Target_9_Locus:
7q35

# Drug_Target_9_Molecular_Weight:
35723

# Drug_Target_9_Name:
Aldose reductase

# Drug_Target_9_Number_of_Residues:
315

# Drug_Target_9_PDB_ID:
1T40

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_9_Protein_Sequence:
>Aldose reductase
ASRLLLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQE
KLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGKE
FFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKPA
VNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAKH
NKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQDMTTLLSYNRNWRVCAL
LSCTSHKDYPFHEEF

# Drug_Target_9_Reaction:
alditol + NAD(P)+ = aldose + NAD(P)H + H+

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies

# Drug_Target_9_SwissProt_ID:
P15121

# Drug_Target_9_SwissProt_Name:
ALDR_HUMAN

# Drug_Target_9_Synonyms:
AR
Aldehyde reductase
EC 1.1.1.21

# Drug_Target_9_Theoretical_pI:
6.99

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB02007
